576:
191:
SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD). Endocyte’s lead drug candidate
254:
announced it would acquire
Endocyte Inc for $ 2.1 billion ($ 24 per share) merging it with a newly created subsidiary. Endocyte will bolster Novartis' offering in its radiopharmaceuticals business, with Endocyte's first in class candidate
478:
Covello, Kelly; Flefleh, Christine; Menard, Krista; Wiebesiek, Amy; McGlinchey, Kelly; Wen, MeiLi; Westhouse, Richard; Reddy, Joe; Vlahov, Iontcho; Hunt, John; Rose, William; Leamon, Chris; Vite, Greg; Lee, Francis (1 May 2008).
547:
620:
610:
645:
630:
625:
548:"Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms"
288:
Potera, Carol (April 2013). "Exploiting Folate
Pathways to Treat Cancer: Endocyte Uses an Imaging Agent to Select Patients Likely to Respond to Its Therapies".
337:
317:
176:, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by
525:
502:
605:
640:
635:
256:
231:), and Christopher Leamon, PhD, the company’s VP of research. This technology is a folic acid-based drug delivery system, referred to now as
356:
235:. The company is also developing SMDCs with varying drug payloads as well as different ligands for other molecular targets, such as
615:
380:
481:"Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development"
236:
224:
201:
184:
196:, an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by
169:
98:
587:
153:
53:
208:, which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of
173:
165:
157:
102:
533:
510:
228:
200:
for $ 120 million in an upfront payment and up to $ 880 million in milestone payments. Vintafolide is a
432:
240:
227:(PSMA) receptors. The company was formed based on technology developed by Philip Low (the company's
161:
480:
421:"Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis"
401:
650:
460:
450:
440:
297:
232:
220:
205:
575:
436:
197:
120:
599:
455:
420:
36:
213:
209:
193:
244:
28:
445:
464:
251:
177:
125:
301:
259:
being targeted against metastatic castration-resistant prostate cancer.
212:. Endocyte retained rights to the development and commercialization of
183:
Endocyte is advancing the first technology platform for the creation of
526:"Novartis pushes deeper into nuclear medicine with $ 2.1 billion deal"
503:"Novartis to buy cancer drugmaker Endocyte for $ 2.1 billion in cash"
42:
357:"Novartis inks $ 2.1B Endocyte buyout, furthering radiotherapy push"
247:-folic acid conjugate (BMS-753493), described at a 2008 conference.
381:"Endocyte's kidney conjugates get right to the spot - FiercePharma"
168:(IPO). As of 2013, the company had 93 employees. The original
219:
Endocyte’s other preclinical drug candidates also target the
338:"Drugmaker Endocyte Rises 29% After Initial Public Offering"
136:
569:
131:
119:
109:
91:
77:
59:
49:
34:
24:
164:. In 2011 the company completed successfully an
156:company established in 1996 and headquartered in
283:
281:
279:
277:
275:
273:
271:
425:Proceedings of the National Academy of Sciences
402:"Endocyte soars on cancer drug deal with Merck"
336:Rapaport, Lisa; Spears, Lee (4 February 2011).
621:Pharmaceutical companies of the United States
396:
394:
204:consisting of a small molecule targeting the
8:
611:Pharmaceutical companies established in 1996
318:Genetic Engineering & Biotechnology News
290:Genetic Engineering & Biotechnology News
19:
646:American subsidiaries of foreign companies
574:
18:
454:
444:
419:Leamon, C. P.; Low, P. S. (1 July 1991).
631:Companies formerly listed on the Nasdaq
267:
626:Health care companies based in Indiana
584:Historical business data for Edocyte:
7:
239:(PSMA) and has also developed, with
237:prostate-specific membrane antigen
225:prostate-specific membrane antigen
14:
509:. 18 October 2018. Archived from
524:Miller, John (18 October 2018).
355:Taylor, Nick Paul (2018-10-18).
16:American pharmaceutical company
606:1996 establishments in Indiana
185:small molecule drug conjugates
1:
641:2018 mergers and acquisitions
636:2011 initial public offerings
202:small molecule drug conjugate
65:; 28 years ago
667:
385:www.fiercedrugdelivery.com
315:"Clinical Trials Update",
570:https://www.endocyte.com
616:West Lafayette, Indiana
446:10.1073/pnas.88.13.5572
166:initial public offering
158:West Lafayette, Indiana
82:West Lafayette, Indiana
536:on November 28, 2018.
513:on November 28, 2018.
491:(9 Supplement): 2326.
250:In mid-October 2018,
241:Bristol-Myers Squibb
162:Purdue Research Park
160:, a resident of the
437:1991PNAS...88.5572L
302:10.1089/gen.33.7.03
111:Number of employees
21:
431:(13): 5572–5576.
154:biopharmaceutical
147:
146:
54:Biopharmaceutical
658:
578:
573:
572:
556:
555:
544:
538:
537:
532:. Archived from
521:
515:
514:
499:
493:
492:
475:
469:
468:
458:
448:
416:
410:
409:
408:. 16 April 2012.
398:
389:
388:
377:
371:
370:
368:
367:
352:
346:
345:
333:
327:
326:
312:
306:
305:
285:
233:folate targeting
143:
140:
138:
73:
71:
66:
22:
666:
665:
661:
660:
659:
657:
656:
655:
596:
595:
592:
568:
567:
564:
559:
546:
545:
541:
523:
522:
518:
501:
500:
496:
485:Cancer Research
477:
476:
472:
418:
417:
413:
400:
399:
392:
379:
378:
374:
365:
363:
354:
353:
349:
335:
334:
330:
314:
313:
309:
287:
286:
269:
265:
221:folate receptor
206:folate receptor
135:
112:
94:
87:
83:
69:
67:
64:
39:
17:
12:
11:
5:
664:
662:
654:
653:
648:
643:
638:
633:
628:
623:
618:
613:
608:
598:
597:
594:
593:
591:
590:
585:
581:
579:
563:
562:External links
560:
558:
557:
539:
516:
494:
470:
411:
390:
372:
361:Fierce Biotech
347:
328:
307:
266:
264:
261:
145:
144:
133:
129:
128:
123:
117:
116:
113:
110:
107:
106:
97:Mike Sherman (
95:
92:
89:
88:
85:
81:
79:
75:
74:
61:
57:
56:
51:
47:
46:
40:
35:
32:
31:
26:
15:
13:
10:
9:
6:
4:
3:
2:
663:
652:
649:
647:
644:
642:
639:
637:
634:
632:
629:
627:
624:
622:
619:
617:
614:
612:
609:
607:
604:
603:
601:
589:
586:
583:
582:
580:
577:
571:
566:
565:
561:
553:
549:
543:
540:
535:
531:
527:
520:
517:
512:
508:
504:
498:
495:
490:
486:
482:
474:
471:
466:
462:
457:
452:
447:
442:
438:
434:
430:
426:
422:
415:
412:
407:
403:
397:
395:
391:
386:
382:
376:
373:
362:
358:
351:
348:
343:
339:
332:
329:
325:(8): 58, 2009
324:
320:
319:
311:
308:
303:
299:
296:(7): 12, 14.
295:
291:
284:
282:
280:
278:
276:
274:
272:
268:
262:
260:
258:
253:
248:
246:
242:
238:
234:
230:
226:
222:
217:
215:
211:
207:
203:
199:
195:
190:
186:
181:
179:
175:
171:
167:
163:
159:
155:
151:
142:
134:
130:
127:
124:
122:
118:
114:
108:
104:
100:
96:
90:
86:United States
80:
76:
62:
58:
55:
52:
48:
44:
41:
38:
33:
30:
27:
23:
551:
542:
534:the original
529:
519:
511:the original
506:
497:
488:
484:
473:
428:
424:
414:
405:
384:
375:
364:. Retrieved
360:
350:
341:
331:
322:
316:
310:
293:
289:
249:
218:
214:etarfolatide
188:
182:
149:
148:
78:Headquarters
25:Company type
588:SEC filings
257:Lu-PSMA-617
223:as well as
210:vinblastine
194:vintafolide
45:: ECYT
600:Categories
366:2022-04-13
263:References
245:epothilone
93:Key people
29:Subsidiary
342:Bloomberg
170:president
139:.endocyte
99:president
37:Traded as
651:Novartis
552:Novartis
252:Novartis
178:Novartis
150:Endocyte
126:Novartis
50:Industry
20:Endocyte
530:Reuters
507:Reuters
465:2062838
433:Bibcode
406:Reuters
132:Website
68: (
60:Founded
463:
453:
189:a.k.a.
121:Parent
43:Nasdaq
456:51919
243:, an
198:Merck
152:is a
461:PMID
172:and
141:.com
101:and
70:1996
63:1996
451:PMC
441:doi
298:doi
229:CSO
192:is
174:CEO
137:www
103:CEO
602::
550:.
528:.
505:.
489:68
487:.
483:.
459:.
449:.
439:.
429:88
427:.
423:.
404:.
393:^
383:.
359:.
340:.
323:29
321:,
294:33
292:.
270:^
216:.
180:.
115:78
84:,
554:.
467:.
443::
435::
387:.
369:.
344:.
304:.
300::
187:(
105:)
72:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.